Novo Nordisk A/S (NYSE:NVO) Shares Unloaded Rep. Byron Donalds

Representative Byron Donalds (R-Florida) recently sold shares of Novo Nordisk A/S (NYSE:NVO). In a filing disclosed on April 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Novo Nordisk A/S stock on March 20th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of GoDaddy (NYSE:GDDY) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Abbott Laboratories (NYSE:ABT) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Gartner (NYSE:IT) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of Equifax (NYSE:EFX) on 3/20/2025.
• Purchased $1,001 – $15,000 in shares of Tradeweb Markets (NASDAQ:TW) on 3/20/2025.
• Sold $1,001 – $15,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 3/20/2025.

Novo Nordisk A/S Stock Down 7.1 %

Shares of NYSE NVO traded down $4.45 on Thursday, reaching $58.43. 13,599,813 shares of the company’s stock traded hands, compared to its average volume of 5,883,584. The business’s 50 day simple moving average is $76.55 and its two-hundred day simple moving average is $92.55. Novo Nordisk A/S has a 12 month low of $57.36 and a 12 month high of $148.15. The company has a market cap of $262.21 billion, a price-to-earnings ratio of 17.75, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were paid a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.54%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Passumpsic Savings Bank boosted its holdings in shares of Novo Nordisk A/S by 0.9% in the third quarter. Passumpsic Savings Bank now owns 21,448 shares of the company’s stock worth $2,554,000 after buying an additional 194 shares during the last quarter. Virtu Financial LLC increased its stake in shares of Novo Nordisk A/S by 69.8% in the 3rd quarter. Virtu Financial LLC now owns 33,929 shares of the company’s stock worth $4,040,000 after purchasing an additional 13,949 shares in the last quarter. Tudor Financial Inc. bought a new position in Novo Nordisk A/S in the 3rd quarter worth $311,000. Anchor Investment Management LLC lifted its position in Novo Nordisk A/S by 2.3% during the third quarter. Anchor Investment Management LLC now owns 13,447 shares of the company’s stock valued at $1,601,000 after purchasing an additional 297 shares in the last quarter. Finally, World Investment Advisors LLC grew its holdings in Novo Nordisk A/S by 36.9% during the third quarter. World Investment Advisors LLC now owns 13,925 shares of the company’s stock valued at $1,655,000 after purchasing an additional 3,750 shares during the period. Institutional investors own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. BMO Capital Markets reiterated a “market perform” rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday. They issued an “underperform” rating for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $135.00.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.